dc.creator | Pantazopoulos I., Magounaki K., Kotsiou O., Rouka E., Perlikos F., Kakavas S., Gourgoulianis K. | en |
dc.date.accessioned | 2023-01-31T09:41:51Z | |
dc.date.available | 2023-01-31T09:41:51Z | |
dc.date.issued | 2022 | |
dc.identifier | 10.3390/jpm12030379 | |
dc.identifier.issn | 20754426 | |
dc.identifier.uri | http://hdl.handle.net/11615/77510 | |
dc.description.abstract | Globally, chronic obstructive pulmonary disease (COPD) remains a major cause of morbidity and mortality, having a significant socioeconomic effect. Several molecular mechanisms have been related to COPD including chronic inflammation, telomere shortening, and epigenetic modifications. Nowadays, there is an increasing need for novel therapeutic approaches for the management of COPD. These treatment strategies should be based on finding the source of acute exacerbation of COPD episodes and estimating the patient’s own risk. The use of biomarkers and the measurement of their levels in conjunction with COPD exacerbation risk and disease prognosis is considered an encouraging approach. Many types of COPD biomarkers have been identified which include blood protein biomarkers, cellular biomarkers, and protease enzymes. They have been isolated from different sources including peripheral blood, sputum, bronchoalveolar fluid, exhaled air, and genetic material. However, there is still not an exclusive biomarker that is used for the evaluation of COPD but rather a combination of them, and this is attributed to disease complexity. In this review, we summarize the clinical significance of COPD-related biomarkers, their association with disease outcomes, and COPD patients’ management. Finally, we depict the various samples that are used for identifying and measuring these biomarkers. © 2022 by the authors. Licensee MDPI, Basel, Switzerland. | en |
dc.language.iso | en | en |
dc.source | Journal of Personalized Medicine | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85126481171&doi=10.3390%2fjpm12030379&partnerID=40&md5=7f2e6aea709c46cc818cef5e3d3d2f93 | |
dc.subject | 8 isoprostane | en |
dc.subject | advanced glycation end product receptor | en |
dc.subject | alpha tocopherol | en |
dc.subject | ascorbic acid | en |
dc.subject | benralizumab | en |
dc.subject | beta thromboglobulin | en |
dc.subject | biological marker | en |
dc.subject | brain derived neurotrophic factor | en |
dc.subject | C reactive protein | en |
dc.subject | carbon monoxide | en |
dc.subject | corticosteroid | en |
dc.subject | eosinophil cationic protein | en |
dc.subject | eosinophil peroxidase | en |
dc.subject | epidermal growth factor receptor | en |
dc.subject | fibrinogen | en |
dc.subject | gamma glutamyltransferase | en |
dc.subject | gelatinase B | en |
dc.subject | glutathione | en |
dc.subject | glutathione peroxidase | en |
dc.subject | glutathione transferase | en |
dc.subject | growth hormone | en |
dc.subject | heme oxygenase | en |
dc.subject | interleukin 6 | en |
dc.subject | interleukin 8 | en |
dc.subject | leptin | en |
dc.subject | leukocyte elastase | en |
dc.subject | macrophage elastase | en |
dc.subject | malonaldehyde | en |
dc.subject | mepolizumab | en |
dc.subject | monocyte chemotactic protein 1 | en |
dc.subject | mucin 5AC | en |
dc.subject | myeloperoxidase | en |
dc.subject | neutrophil collagenase | en |
dc.subject | nitric oxide | en |
dc.subject | plasminogen activator inhibitor 1 | en |
dc.subject | platelet endothelial cell adhesion molecule 1 | en |
dc.subject | prasterone | en |
dc.subject | procalcitonin | en |
dc.subject | protein p21 | en |
dc.subject | proteinase | en |
dc.subject | reactive oxygen metabolite | en |
dc.subject | retinol | en |
dc.subject | sirtuin 1 | en |
dc.subject | superoxide dismutase | en |
dc.subject | thiobarbituric acid reactive substance | en |
dc.subject | thrombocyte factor 4 | en |
dc.subject | toll like receptor 10 | en |
dc.subject | troponin | en |
dc.subject | tryptase | en |
dc.subject | tumor necrosis factor | en |
dc.subject | vasculotropin | en |
dc.subject | von Willebrand factor | en |
dc.subject | apoptosis | en |
dc.subject | blood cell count | en |
dc.subject | bronchoscopy | en |
dc.subject | chronic inflammation | en |
dc.subject | chronic obstructive lung disease | en |
dc.subject | cytotoxicity | en |
dc.subject | disease exacerbation | en |
dc.subject | disease severity | en |
dc.subject | eosinophil count | en |
dc.subject | eosinophilia | en |
dc.subject | epigenetic modification | en |
dc.subject | exhaled breath condensate | en |
dc.subject | expired air | en |
dc.subject | forced expiratory flow | en |
dc.subject | forced expiratory volume | en |
dc.subject | forced vital capacity | en |
dc.subject | fractional exhaled nitric oxide | en |
dc.subject | genetic polymorphism | en |
dc.subject | genomic instability | en |
dc.subject | glycosylation | en |
dc.subject | hospitalization | en |
dc.subject | human | en |
dc.subject | hypertension | en |
dc.subject | inflammation | en |
dc.subject | iron binding capacity | en |
dc.subject | leukocyte count | en |
dc.subject | lung cancer | en |
dc.subject | lung function | en |
dc.subject | lung lavage | en |
dc.subject | morbidity | en |
dc.subject | mortality | en |
dc.subject | nose polyp | en |
dc.subject | outcome assessment | en |
dc.subject | oxidative stress | en |
dc.subject | pathogenesis | en |
dc.subject | phenotype | en |
dc.subject | physical activity | en |
dc.subject | prognosis | en |
dc.subject | pulmonary hypertension | en |
dc.subject | Review | en |
dc.subject | risk assessment | en |
dc.subject | smoking cessation | en |
dc.subject | spirometry | en |
dc.subject | sputum | en |
dc.subject | telomere length | en |
dc.subject | telomere shortening | en |
dc.subject | MDPI | en |
dc.title | Incorporating Biomarkers in COPD Management: The Research Keeps Going | en |
dc.type | other | en |